

IgA Nephropathy- Pipeline Insight, 2021

<https://marketpublishers.com/r/I8DAAA1DE922EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: I8DAAA1DE922EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "IgA Nephropathy – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

IgA Nephropathy Understanding

IgA Nephropathy: Overview

IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.

“IgA Nephropathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines. The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.

IgA Nephropathy Emerging Drugs Chapters

This segment of the IgA Nephropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

IgA Nephropathy Emerging Drugs

Atrasentan: Chinook Therapeutics

Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics plans to initiate a phase 3 trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.

IONIS-FB-LRx: Ionis Pharmaceuticals

IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Ionis Pharmaceuticals is leading phase II trials for IONIS-FB-LRx.

Sparsentan: Travere Therapeutics

Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis (FSGS) in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.

Further product details are provided in the report.....

IgA Nephropathy: Therapeutic Assessment

This segment of the report provides insights about the different IgA Nephropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in IgA Nephropathy

There are approx. 10+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. phase III include, Chinook Therapeutics.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

IgA Nephropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgA Nephropathy therapeutic drugs key

players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgA Nephropathy drugs.

IgA Nephropathy Report Insights

IgA Nephropathy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

IgA Nephropathy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing IgA Nephropathy drugs?

How many IgA Nephropathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgA Nephropathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgA Nephropathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for IgA Nephropathy and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis AG

Reata Pharmaceuticals

Chinook Therapeutics

Aravive, Inc.

Omeros Corporation

Travere Therapeutics

Calliditas Therapeutics

Vera Therapeutics, Inc.

Apellis Pharmaceuticals, Inc.

Key Products

Atrasentan

LNP023

Nefecon

Sparsentan

BION-301

AVB-500

IONIS-FB-LRx

APL-2

Contents

- Introduction
- Executive Summary
- IgA Nephropathy: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- IgA Nephropathy – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - IgA Nephropathy companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- IgA Nephropathy Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Atrasentan: Chinook Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- IONIS-FB-LRx: Ionis Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

BION-1301: Chinook Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

IgA Nephropathy Key Companies

IgA Nephropathy Key Products

IgA Nephropathy- Unmet Needs

IgA Nephropathy- Market Drivers and Barriers

IgA Nephropathy- Future Perspectives and Conclusion

IgA Nephropathy Analyst Views

IgA Nephropathy Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for IgA Nephropathy
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for IgA Nephropathy
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: IgA Nephropathy- Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/l8DAAA1DE922EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l8DAAA1DE922EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970